Skip to main content
 

News Releases

Keyword Search
 
2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
05/16/13HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be WebcastPrinter Friendly Version
05/10/13HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be WebcastPrinter Friendly Version
04/29/13HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012Printer Friendly Version
04/15/13HeartWare Schedules First Quarter Conference Call And WebcastPrinter Friendly Version
03/18/13HeartWare International, Inc. Announces Closing of Public Offering of Common StockPrinter Friendly Version
03/12/13HeartWare International, Inc. Announces Pricing of Public Offering of Common StockPrinter Friendly Version
03/11/13HeartWare International, Inc. Announces Public Offering of Common StockPrinter Friendly Version
03/06/13HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be WebcastPrinter Friendly Version
02/28/13HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be WebcastPrinter Friendly Version
02/27/13HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 MillionPrinter Friendly Version
02/19/13HeartWare Schedules Fourth Quarter Conference Call and WebcastPrinter Friendly Version
02/08/13HeartWare Presentation at Leerink Swann Global Healthcare Conference to be WebcastPrinter Friendly Version
01/07/13HeartWare International Announces Preliminary Fourth Quarter 2012 RevenuesPrinter Friendly Version
01/03/13HeartWare Presentation At The 31st Annual J.P. Morgan Healthcare Conference To Be WebcastPrinter Friendly Version
12/06/12HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be WebcastPrinter Friendly Version
11/20/12HeartWare Receives FDA Approval for HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation for Patients with Advanced Heart FailurePrinter Friendly Version
11/16/12HeartWare Presentation At The 24th Annual Piper Jaffray Healthcare Conference To Be WebcastPrinter Friendly Version
11/09/12HeartWare Reports Third Quarter 2012 ResultsPrinter Friendly Version
11/09/12HeartWare Presentation At The Lazard Capital Markets 9th Annual Healthcare Conference To Be WebcastPrinter Friendly Version
11/01/12HeartWare Schedules Third Quarter Conference Call And WebcastPrinter Friendly Version
09/14/12HeartWare Presentation at the UBS Global Life Sciences Conference to be WebcastPrinter Friendly Version
08/10/12HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be WebcastPrinter Friendly Version
08/09/12HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be WebcastPrinter Friendly Version
08/07/12HeartWare Reports Second Quarter 2012 ResultsPrinter Friendly Version
08/02/12HeartWare Completes Acquisition Of World Heart CorporationPrinter Friendly Version
07/30/12HeartWare Schedules Second Quarter Conference Call And WebcastPrinter Friendly Version
07/09/12HeartWare Names Peter F. McAree Chief Financial OfficerPrinter Friendly Version
05/23/12HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart FailurePrinter Friendly Version
05/23/12HeartWare Announces Publication Of Results From U.S. Bridge-To-Transplant Clinical TrialPrinter Friendly Version
05/10/12HeartWare International Reports First Quarter 2012 Revenue of $26.3 Million; 47% Increase From $18.0 Million in First Quarter 2011Printer Friendly Version
05/08/12HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical TrialPrinter Friendly Version
05/07/12HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be WebcastPrinter Friendly Version
05/03/12Heartware Schedules First Quarter Conference Call And WebcastPrinter Friendly Version
04/25/12FDA Advisory Committee Votes in Favor of HeartWare® Ventricular Assist System as Bridge to Transplant for Patients With End-Stage Heart FailurePrinter Friendly Version
04/25/12HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart TransplantationPrinter Friendly Version
03/29/12HeartWare International Expands Intellectual Property and Technology Portfolio Through Definitive Agreement to Acquire World Heart Corporation for US$8 MillionPrinter Friendly Version
03/16/12HeartWare Receives 54-Patient Allotment From FDA Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical TrialPrinter Friendly Version
03/06/12HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be WebcastPrinter Friendly Version
02/16/12HeartWare International Reports Fourth Quarter 2011 Revenues of $23.1 Million; Full Year 2011 Revenues of $82.8 Million; 50% Increase From $55.2 Million in 2010Printer Friendly Version
02/14/12HeartWare Announces Date for FDA Advisory Committee PanelPrinter Friendly Version
02/06/12HeartWare Schedules Fourth Quarter Conference Call and WebcastPrinter Friendly Version
01/09/12HeartWare and Dualis MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist SystemPrinter Friendly Version
01/04/12HeartWare to Webcast Presentation at the 30th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
12/09/11HeartWare to Present at the Oppenheimer 22nd Annual Healthcare ConferencePrinter Friendly Version
11/23/11HeartWare to Present at the 23rd Annual Piper Jaffray Health Care ConferencePrinter Friendly Version
11/10/11HeartWare to Present at the Lazard Capital Markets 8th Annual Healthcare ConferencePrinter Friendly Version
11/04/11HeartWare to Present at the Credit Suisse 2011 Healthcare ConferencePrinter Friendly Version
10/27/11HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010Printer Friendly Version
10/27/11HeartWare International Announces Planned Departure of Chief Financial OfficerPrinter Friendly Version
10/21/11HeartWare Schedules Third Quarter Conference Call and WebcastPrinter Friendly Version
10/02/11HeartWare Reports Additional Clinical Data From Bridge-to-Transplant and Continued Access Patients at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Meeting in LisbonPrinter Friendly Version
09/28/11HeartWare Announces Presentation of Clinical Data at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in LisbonPrinter Friendly Version
09/19/11HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device DayPrinter Friendly Version
09/14/11HeartWare to Present at the UBS Global Life Sciences ConferencePrinter Friendly Version
09/09/11HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP CongressPrinter Friendly Version
08/12/11HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access ConferencePrinter Friendly Version
08/08/11HeartWare to Present at the Canaccord Genuity 31st Annual Growth ConferencePrinter Friendly Version
08/04/11HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010Printer Friendly Version
07/27/11HeartWare to Report Financial Results for Second Quarter of 2011Printer Friendly Version
06/16/11HeartWare to Present at the Wells Fargo 2011 Healthcare ConferencePrinter Friendly Version
05/06/11HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care ConferencePrinter Friendly Version
05/05/11HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010Printer Friendly Version
04/28/11HeartWare Supplemental Addendum to CE Mark Accepted by BSIPrinter Friendly Version
04/26/11HeartWare to Report 2011 First Quarter Financial ResultsPrinter Friendly Version
04/15/11HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access PatientsPrinter Friendly Version
04/12/11HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual MeetingPrinter Friendly Version
03/24/11HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in AustraliaPrinter Friendly Version
03/07/11HeartWare to Present at the Barclays Capital 2011 Global Healthcare ConferencePrinter Friendly Version
02/24/11HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009Printer Friendly Version
02/15/11HeartWare to Report 2010 Fourth Quarter and Year-End Financial ResultsPrinter Friendly Version
01/24/11HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical TrialPrinter Friendly Version
01/04/11HeartWare to Present at the 29th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
12/28/10HeartWare Files PMA Application for FDA Approval of the HeartWare(R) Ventricular Assist System for a Bridge-to-Transplant IndicationPrinter Friendly Version
12/15/10HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common StockPrinter Friendly Version
12/10/10HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common StockPrinter Friendly Version
12/09/10HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common StockPrinter Friendly Version
12/02/10HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity ConferencePrinter Friendly Version
11/18/10HeartWare to Present at the 22nd Annual Piper Jaffray Health Care ConferencePrinter Friendly Version
11/14/10HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial, ADVANCEPrinter Friendly Version
11/11/10HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare ConferencePrinter Friendly Version
11/09/10HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010Printer Friendly Version
11/03/10HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009Printer Friendly Version
10/20/10HeartWare to Report Financial Results for Third Quarter of 2010Printer Friendly Version
09/23/10Appendix 3BPrinter Friendly Version
09/23/10HeartWare to Present at Lazard Capital Markets Circulatory Assist Device DayPrinter Friendly Version
09/15/10HeartWare to Present at the UBS 2010 Global Life Sciences ConferencePrinter Friendly Version
09/03/10HeartWare Receives Second Patient Allotment Under Continued Access Protocol for Pivotal U.S. Bridge-To-Transplant Clinical TrialPrinter Friendly Version
08/05/10HeartWare International Reports Second Quarter 2010 Revenues of $9.8 Million; Compared to $3.0 Million in Second Quarter 2009Printer Friendly Version
08/04/10HeartWare to Present at The Canaccord Genuity 30th Annual Growth ConferencePrinter Friendly Version
07/29/10HeartWare to Present at the Wedbush Securities 2010 Life Sciences Best Ideas ConferencePrinter Friendly Version
07/27/10HeartWare to Report Financial Results for Second Quarter of 2010Printer Friendly Version
06/24/10HeartWare Announces Board SuccessionPrinter Friendly Version
06/17/10HeartWare to Present at the Wells Fargo Securities 2010 Healthcare ConferencePrinter Friendly Version
06/14/10HeartWare Receives Conditional FDA Approval to Commence Pivotal Destination Therapy Clinical Trial in the U.S.Printer Friendly Version
05/06/10HeartWare to Present at Bank of America Merrill Lynch Health Care Conference in New YorkPrinter Friendly Version
05/03/10HeartWare International Reports First Quarter 2010 Revenues of $10.7 Million; Compared With $1.5 Million In First Quarter 2009Printer Friendly Version
04/26/10HeartWare Initiates Repairs and Partial Recall of ControllersPrinter Friendly Version
04/23/10HeartWare Data From First 100 Patients in International Clinical and Commercial Experience Shows 90% Survival at 180 DaysPrinter Friendly Version
04/12/10HeartWare to Report Financial Results for First Quarter of 2010Printer Friendly Version
04/07/10HeartWare Receives FDA Approval of Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical TrialPrinter Friendly Version
03/11/10HeartWare to Present at the Barclays Capital 2010 Global Healthcare ConferencePrinter Friendly Version
03/04/10HeartWare to Present at the Roth Capital Partners OC Growth Stock ConferencePrinter Friendly Version
02/22/10HeartWare International Reports Fourth Quarter Revenues of $12.2 Million; Full Year 2009 Revenues of $24.2 MillionPrinter Friendly Version
02/22/10HeartWare Announces Early Conclusion of Enrollment for U.S. Bridge-to-Transplant Clinical TrialPrinter Friendly Version
02/08/10HeartWare to Report 2009 Fourth Quarter and Year-End Financial ResultsPrinter Friendly Version
02/02/10HeartWare International, Inc. Announces Completion of Public Offering of Common StockPrinter Friendly Version
01/27/10HeartWare International, Inc. Announces Pricing of Public Offering of Common StockPrinter Friendly Version
01/26/10HeartWare International, Inc. Announces Commencement of Public Offering of Common StockPrinter Friendly Version
01/06/10HeartWare to Present at J.P. Morgan Healthcare Conference in San FranciscoPrinter Friendly Version
11/25/09HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York CityPrinter Friendly Version
11/06/09HeartWare to Present at Upcoming Investment Conferences in NovemberPrinter Friendly Version
11/04/09HeartWare International Reports Third Quarter Revenues of $7.5 MillionPrinter Friendly Version
10/29/09Advance Notice of Q3 Earnings CallPrinter Friendly Version
10/05/09U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical TrialPrinter Friendly Version
09/01/09HeartWare International, Inc. Temporary Suspension of TradingPrinter Friendly Version
08/20/09HeartWare International Surpasses 50 Implants in the USPrinter Friendly Version
08/17/09HeartWare International, Inc. Closes US$60 Million FinancingPrinter Friendly Version
08/11/09HeartWare to Present at Canaccord Adams 29th Annual Global Growth ConferencePrinter Friendly Version
08/10/09HeartWare International, Inc. Announces US$55 Million FinancingPrinter Friendly Version
07/31/09Thoratec Corporation and HeartWare International, Inc. Announce Termination of Proposed TransactionPrinter Friendly Version
07/29/09U.S. Federal Trade Commission to Challenge Thoratec's Proposed Acquisition of HeartWare InternationalPrinter Friendly Version
05/12/09HeartWare to Present at Eighth Annual JMP Securities Research ConferencePrinter Friendly Version
04/24/09HeartWare International Clinical Trial Shows 90% Survival at 180 DaysPrinter Friendly Version